Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Nutritional profiles differed: SADI-S was associated with lower calcium, zinc, folate, and vitamin D levels, whereas RYGB patients had lower vitamin B12.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This retrospective cohort study compared the long-term outcomes in patients undergoing revisional bariatric surgery after insufficient weight loss after sleeve gastrectomy (SG) or weight recurrence.

Source: Methods.

Patients were excluded if they received a revisional operation other than RYGB or SADI-S, if revision was performed solely for non-weight-related complications such as GERD or stricture, or if they did not follow-up adequately after the operation.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Comparative seven year outcomes of RYGB and SADI-S as revisional procedures for weight recurrence regain after sleeve gastrectomy: weight loss trajectory, reflux control, and metabolic safety

Cohort study · Surgical Endoscopy · 2026

Original publication title

Comparative seven year outcomes of RYGB and SADI-S as revisional procedures for weight recurrence regain after sleeve gastrectomy: weight loss trajectory, reflux control, and metabolic safety

Asaad F. Salama; Abdelwahed Yahmadi; Hamzah El Baba; Jawher Baazaoui; Khadija Gibreal; Mohamed Bougmiza; Mohammed Al Kuwari

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This 7-year comparative analysis demonstrates that both Roux-en-Y gastric bypass and single-anastomosis duodeno-ileal bypass are effective and safe revisional procedures for inadequate weight loss after sleeve gastrectomy. Both operations produced durable long-term weight reduction with acceptable complication rates when supported by structured follow-up and nutritional monitoring.

However, clinically meaningful differences were evident. SADI-S yielded superior long-term weight-loss outcomes, reflected in higher total and excess weight loss and greater BMI reduction at 1, 5, and 7 years. These findings highlight the stronger malabsorptive effect of SADI-S, particularly benefiting patients with higher pre-revisional weight or significant weight regain after sleeve gastrectomy.

In contrast, RYGB demonstrated a clear advantage in managing gastroesophageal reflux disease, achieving substantially higher rates of symptom resolution. Outcomes related to other obesity-associated comorbidities, including diabetes and hypertension, were similar between procedures. Although nutritional parameters differed, severe malnutrition and major surgical complications remained infrequent in both groups.

Overall, these results support a personalized approach to revisional bariatric surgery, balancing long-term weight-loss goals, symptom control, and nutritional risk. Lifelong follow-up remains essential to optimize outcomes and sustain the benefits of either revisional strategy.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Sleeve gastrectomy (SG) is widely performed, yet 20 to 50% of patients experience insufficient weight loss or weight regain, leading to revisional surgery. Roux-en-Y gastric bypass (RYGB) and single-anastomosis duodeno-ileal bypass (SADI-S) are two commonly used revisional procedures, but long-term comparative data remain limited. This study evaluates 7-year outcomes of RYGB versus SADI-S as revisional surgeries for weight recurrence after SG.

Source: Background

Study methods

What methods does the paper describe?

This retrospective cohort study compared the long-term outcomes in patients undergoing revisional bariatric surgery after insufficient weight loss after sleeve gastrectomy (SG) or weight recurrence. Suboptimal outcomes after sleeve gastrectomy were defined according to accepted international standards as either insufficient weight loss: defined as a percentage of total weight loss (%TWL) of less than 20% and/or a percentage of excess weight loss (%EWL) of less than 50% at 18 to 24 months postoperatively: or significant weight regain following an initial satisfactory weight loss response [10, 11].

The study included all adult patients who underwent either RYGB or SADI-S at our institution between January 1, 2014, and December 31, 2015. The insufficient weight loss or severe weight recurrence regain was to be revised according to the clinical standards of failed SG. Patients were excluded if they received a revisional operation other than RYGB or SADI-S, if revision was performed solely for non-weight-related complications such as GERD or stricture, or if they did not follow-up adequately after the operation.

A total of 105 patients met the inclusion criteria and were included: 62 RYGB and 43 SADI-S patients.

Surgical technique

All procedures were performed as revisional laparoscopic procedures after SG, and none were converted to open procedures.

RYGB: The Roux-en-Y gastric bypass was performed using a standardized technique. A small gastric pouch (30 to 50 ml) was fashioned by transecting the previously sleeved stomach approximately 4 cm distal to the gastroesophageal junction with additional trimming performed when necessary to optimize pouch configuration. The alimentary (Roux) limb was constructed with a length of 100 cm, and the biliopancreatic limb measured 125 cm. Both Petersen’s space and the mesenteric defect at the jejunojejunostomy were systematically closed to minimize the risk of internal herniation.

No intra-abdominal drains were routinely placed.

SADI-S: After inspection of the abdominal cavity, a retropyloric-retroduodenal dissection was carried out to expose approximately 3 cm of the duodenum distal to the pylorus, which was then transected. The small bowel length was measured from the ileocecal junction, and a 300-cm ileal common channel was constructed. A double layer end: to: side duodeno-ileal anastomosis was created in an isoperistaltic fashion. No intra-abdominal drains were routinely placed.

Demographic and baseline clinical data were obtained from electronic medical records. The variables included age, sex, height, weight prior to SG, nadir weight after SG, and weight prior to revisional surgery. Comorbidity data were collected and classified as diabetes, hypertension, dyslipidemia, asthma, obstructive sleep apnea, and GERD.

Perioperative variables, including operative time and length of stay, were also extracted. Laboratory markers, including hemoglobin, micronutrients, lipid profile, ferritin, folate, vitamin B12, and vitamin D, were recorded at baseline, 1, 5, and 7 years to assess nutritional status at later time points.

At 1-, 5-, and 7-year post-revision follow-up, anthropometric measurements were obtained. Variables included body weight, BMI, percentage excess weight loss (percent EWL), percentage total weight loss (percent TWL), and body weight reduction.

All complications after the operation, such as bleeding, internal hernia, marginal ulcers, dumping syndrome, severe malnutrition, vitamin deficiencies, and iron deficiency anemia, were carefully reviewed through electronic records from surgery to the date of data collection.

The SPSS version 26 was used to perform statistical analysis. Independent samples based on distributions (either independent-sample t-tests or Mann Whitey U tests). Chi-square test or Fisher exact test was used to analyze categorical variables. Kaplan Meier curves were used to determine time-to-event data (e.g., complication-free survival), whereas Cox proportional hazards techniques were employed to estimate outcome predictors. A p-value < 0.05 was considered statistically significant.

Source: Methods Source: Methods

Results: Baseline characteristics

The study examined 105 individuals who returned to surgery after unsuccessful sleeve gastrectomy to perform a revisional bariatric surgery, 62 underwent conversion to RYGB, and 43 were converted from SG to SADI-S. The age of both groups was similar as the mean age of RYGB was 40.66 years, SD 9.47, and that of SADI-S was 39.35 years, SD 9.28 (p = 0.48). But there was significant difference in sex distribution. Females constituted 65.8 percent of the RYGB group and 61.5 percent of the SADI-S group (p = 0.01), indicating that there might be gender-related factors that affect the surgical decision-making [4, 5].

Also, SADI-S patients were revised earlier with an average of 3.53 ± 1.29 years after SG as opposed to 4.13 ± 1.31 years in RYGB patients (p = 0.02). It could be indicative of a rapid weight recurrence regain after SG in subjects who received SADI-S as a revisional conversion surgery (Table 1).

Table 1

Baseline characteristics

VariableRYGB (n = 62)
Mean (SD)
SADI-S (n = 43)
Mean (SD)
P-value
Age (years)40.66 (9.47)39.35 (9.28)0.48
Sex (M/F) n (%)
 F52 (65.8)27 (34.2)0.01*
 M10 (38.5)16 (61.5)
Years from LSG to revision4.13 (1.31)3.53 (1.29)0.02*
Height (cm)162.85 (6.91)165.12 (8.64)0.14
Weight before LSG (kg)128.73 (26.95)141.02 (27.14)0.02*
BMI before LSG (kg/m2)48.15 (8.25)50.40 (11.46)0.24
Lowest weight after LSG (kg)90.07 (18.00)101.84 (21.58)0.005*
Lowest BMI after LSG (kg/m2)33.76 (6.13)32.92 (13.99)0.71
Weight before revisional surgery (kg)107.16 (21.20)119.05 (23.53)0.008*
BMI before revisional surgery (kg/m2)40.22 (6.45)43.51 (7.07)0.01*
ASA score (I: IV)2.15 (0.39)2.12 (0.39)0.7

*F females, M males, LSG laparoscopic sleeve gastrectomy, BMI body mass index, ASA American Society of Anesthesiologists

Anthropometric measurements (Table 1), indicated that SADI-S patients exhibited higher body weight both before SG and prior to revision. Their pre-SG weight was 141.02/27.14 kg on average in comparison to 128.73/26.95 kg in RYGB patients (p = 0.02). Pre-revision weight was also significantly higher in the SADI-S group (119.05 + 23.53 kg) compared with the RYGB group (107.16 + 21.20 kg; p = 0.008). Accordingly, the SADI-S group had a significantly higher pre-revision BMI (43.51 ± 7.07 kg/m2) compared with the RYGB group (40.22 ± 6.45 kg/m2; p = 0.01) [12Not reported14].

Source: Baseline characteristics Source: Baseline characteristics

Results: Pre-operative comorbidities

The RYGB and SADI-S groups showed comparable preoperative comorbidity profiles (Table 2). The prevalence of diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and asthma did not differ significantly between groups. Diabetes was present in 11 RYGB and 7 SADI-S patients, and hypertension in 11 and 8 patients, respectively, with non-significant p-values. Although dyslipidemia appeared more frequently in the RYGB group (71.4 vs. 28.6%) (Table 2).

Table 2

Co-morbidities pre-op

VariableRYGB
N (%)
SADI-S
N (%)
P-value
Diabetes
 No51 (58.6)36 (41.4)0.84
 Yes11 (61.1)7 (38..9)
Hypertension
 No51 (59.3)35 (40.7)0.9
 Yes11 (57.9)8 (42.1)
Dyslipidaemia
 No52 (57.1)39 (42.9)0.31
 Yes10 (71.4)4 (28.6)
OSA
 No60 (58.3)43 (41.7)0.64
 Yes2 (100.0)0 (0.0)
Asthma
 No55 (57.3)41 (42.7)0.40
 Yes7 (77.8)2 (22.2)
GERD
 No31 (44.3)39 (55.7)0.001*
 Yes31 (88.6)4 (11.4)

*OSA obstructive sleep apnea, GERD gastro-esophageal reflux disease

The only significant difference in preoperative comorbidities was the markedly higher prevalence of GERD among RYGB patients (88.6 vs. 11.4%, p = 0.001). This disparity indicates that GERD was a major determinant in selecting RYGB, consistent with its established efficacy in managing refractory reflux [12]. In contrast, the low prevalence of GERD among SADI-S patients suggests that their revisions were primarily driven by weight-related indications.

Source: Pre-operative comorbidities Source: Pre-operative comorbidities

Results: Anthropometric outcomes

During the 7-year follow-up, SADI-S consistently achieved superior weight-loss outcomes compared with RYGB (Table 4). Although absolute weight and BMI were similar between groups at each assessment point, SADI-S produced significantly greater reductions in %EWL (53.75 vs. 43.46%, p = 0.05), %TWL (21.63 vs. 15.03%, p = 0.001), and BMI (9.54 vs. 6.07, p < 0.001) at 1 year (Table 4).

Table 4

Anthropometric outcomes comparison of RYGB and SADI-S

RYGB (n = 62)SADI-S (n = 43)P-value
Weight at 1 year89.16 (17.99)93.45 (18.11)0.30
BMI at 1 year33.73 (5.69)34.09 (6.12)0.76
%EWL at 1 year43.46 (27.49)53.75 (22.83)0.05
%TWL at 1 year15.03 (8.43)21.63 (8.25)0.000
BMI reduction at 1 year6.07 (3.44)9.54 (4.08)0.000
Weight at 5 years92.15 (19.27)93.07 (15.58)0.79
BMI at 5 years34.67 (6.00)34.34 (5.85)0.78
%EWL at 5 years34.94 (36.46)49.67 (30.13)0.03
%TWL at 5 years12.49 (10.66)20.52 (12.09)0.001
BMI reduction at 5 years5.13 (4.69)9.27 (6.28)0.000
Weight at 7 years92.17 (21.05)94.89 (16.49)0.49
BMI at 7 years34.64 (6.80)34.73 (5.52)0.94
%EWL at 7 years37.53 (41.24)46.67 (29.36)0.23
%TWL at 7 years13.23 (12.28)19.59 (11.97)0.01
BMI reduction at 7 years5.44 (4.96)8.94 (6.08)0.002

These advantages persisted long-term. At 5 years, SADI-S maintained higher %EWL (49.67 vs. 34.94%, p = 0.03), %TWL (20.52 vs. 12.49%, p = 0.001), and BMI reduction (9.27 vs. 5.13, p < 0.001). By 7 years, absolute weight and BMI were comparable, yet SADI-S continued to show superior %TWL (19.59 vs. 13.23%, p = 0.01) and BMI reduction (8.94 vs. 5.44, p = 0.002). These findings are clearly depicted in Fig. 1.

Fig. 1

Comparative long-term weight loss trajectories after revisional RYGB and SADI-S. Mean percentage excess weight loss (%EWL), percentage total weight loss (%TWL), and body mass index (BMI) reduction are reported at 1, 5, and 7 years after revisional surgery. SADI-S consistently showed higher %EWL and %TWL and greater BMI reduction than RYGB across all follow-up intervals. Values are reported as means with standard deviation. RYGB is shown in orange and SADI-S in green (Color figure online)

Figure image at the original source: open the original paper. This file is not included in this text import.

Collectively, these findings indicate that SADI-S provides more durable and clinically meaningful weight-loss outcomes than RYGB as a revisional surgery after inadequate weight loss following sleeve gastrectomy.

Source: Anthropometric outcomes Source: Anthropometric outcomes Source: Anthropometric outcomes

Results: Postoperative laboratory outcomes

Postoperative laboratory assessments (Table 5), at 1, 5, and 7 years demonstrated distinct differences in malabsorption-related parameters between the RYGB and SADI-S groups. Hemoglobin levels remained comparable across all time points. In contrast, calcium levels were consistently lower in the SADI-S group at 5 and 7 years (p = 0.00 and p = 0.04) (Table 5).

Table 5

Post-op lab tests (1, 5, and 7 years) comparison of RYGB and SADI-S

RYGB (n = 62)SADI-S (n = 43)P-Value
Hb_1year11.91 (1.82)11.71 (2.54)0.77
Hb_5year11.78 (1.64)12.07 (2.07)0.43
Hb_7year11.91 (1.77)11.78 (1.31)0.70
Cholesterol_1year4.87 (1.40)4.05 (0.80)0.002*
Cholesterol_5year4.51 (0.93)4.08 (0.77)0.02*
Cholesterol_7year4.65 (0.85)4.21 (0.71)0.01*
TG_1year1.04 (0.49)0.92 (0.53)0.28
TG_5year1.06 (0.52)0.77 (0.24)0.001*
TG_7year0.99 (0.47)0.77 (0.28)0.006*
HDL_1year1.51 (0.37)1.28 (0.29)0.001*
HDL_5year1.55 (0.44)1.33 (0.28)0.007*
HDL_7year1.59 (0.48)1.42 (0.27)0.03*
LDL_Calc_1year2.67 (0.63)2.34 (0.72)0.02*
LDL_Calc_5year2.50 (0.77)2.39 (0.60)0.49
LDL_Calc_7year2.58 (0.69)2.43 (0.62)0.27
Iron_1year10.32 (5.86)12.7 (6.32)0.09
Iron_5year9.29 (4.87)11.51 (6.15)0.10
Iron_7year11.41 (5.96)10.77 (5.32)0.65
HbA1C_1year5.28 (0.60)5.08 (0.40)0.08
HbA1C_5year5.52 (0.65)5.29 (0.53)0.08
HbA1C_7year5.52 (0.71)5.48 (0.69)0.78
Copper_1year17.99 (4.83)15.98 (4.38)0.22
Copper_5year19.10 (3.70)18.21 (5.05)0.59
Copper_7year17.73 (7.87)17.01 (3.93)0.80
Zink_1year10.83 (2.48)9.41 (2.36)0.02*
Zink_5year11.35 (2.19)9.94 (1.53)0.01*
Zink_7year10.61 (1.73)9.51 (1.30)0.04*
Vit D_1year19.49 (10.98)13.90 (7.43)0.005*
Vit D_5year27.92 (23.10)16.43 (10.59)0.02*
Vit D_7year23.79 (13.80)22.11 (10.09)0.52
Ferritin_1year63.66 (149.49)57.15 (64.66)0.83
Ferritin_5year108.19 (203.02)91.47 (184.71)0.71
Ferritin_7year104.15 (238.01)75.51 (120.47)0.55
Folate_1year24.70 (11.59)13.20 (7.71)0.00*
Folate_5year28.42 (12.18)16.52 (12.09)0.01*
Folate_7year27.81 (13.88)14.22 (9.96)0.00*
Vit B12_1year260.69 (136.87)386.53 (282.82)0.01*
Vit B12_5year209.19 (115.39)405.54 (329.00)0.02*
Vit B12_7year256.21 (140.88)465.25 (285.78)0.00*

Lipid profiles showed more pronounced differences. SADI-S patients exhibited significantly lower total cholesterol at 1, 5, and 7 years (p = 0.002, 0.02, and 0.01), and lower triglycerides at 5 and 7 years (p = 0.001 and 0.006), alongside reduced HDL and LDL at all assessments, with LDL reaching statistical significance at 1 year.

Micronutrient evaluation revealed higher zinc and folate levels in RYGB patients. In contrast, vitamin B12 concentrations were consistently higher after SADI-S.

Source: Postoperative laboratory outcomes Source: Postoperative laboratory outcomes Source: Postoperative laboratory outcomes

Results: Comorbidity outcomes

Comorbidity outcomes (Table 6) were largely comparable between RYGB and SADI-S, with no statistically significant differences for type 2 diabetes, hypertension, dyslipidemia, or asthma.

Table 6

Comorbidity outcomes comparison of RYGB versus SADI after sleeve gastrectomy

VariableRYGB
N (%)
SADI-S
N (%)
p-value*
Diabetes
 Complete remission or improved4 (44.4)5 (55.6)0.24
 No changes/worse6 (85.7)1 (14.3)
Hypertension
 Complete remission or improved0 (0.0)2 (100.0)0.38
 No changes/worse8 (61.5)5 (38.5)
Dyslipidemia
 Complete remission or improved6 (66..7)3 (33.3)0.99
 No changes/worse2 (50.0)2 (50.0)
Asthma
 Complete remission or improved2 (100.0)0 (0.0)0.99
 No change/worse2 (66.7)1 (33.3)
GERD
 Complete remission or improved19 (95.0)1 (5.0)0.02*

Diabetes remission or improvement occurred in 44.4% of RYGB and 55.6% of SADI-S patients (p = 0.24). Hypertension outcomes were similar overall, with improvement observed only in the SADI-S group (Table 6).

Dyslipidemia remission or improvement was 66.7% in RYGB and 33.3% in SADI-S (p = 0.99).

Asthma improvement rates were low and did not differ between procedures.

In contrast, GERD outcomes favored RYGB: complete remission or improvement occurred in 95.0 versus 5.0% with SADI-S (p = 0.02), and persistent or progressive GERD was more common after SADI-S.

Source: Comorbidity outcomes Source: Comorbidity outcomes Source: Comorbidity outcomes Source: Comorbidity outcomes Source: Comorbidity outcomes

What strengths and limitations does the paper describe?

Strengths

  • Long-term follow-up: The study provides 7-year outcomes, offering rare long-term comparative data on RYGB and SADI-S as revisional procedures: a time horizon seldom reported in the literature.

  • Direct comparison of two major revisional techniques: The analysis contrasts two of the most commonly performed revisional operations after failed sleeve gastrectomy, enabling meaningful clinical comparisons in weight-loss durability, metabolic outcomes, and safety.

  • Comprehensive clinical assessment: Anthropometric, biochemical, metabolic, and comorbidity-related data were systematically collected at multiple time points (baseline, 1, 5, and 7 years), strengthening the robustness of outcome evaluation.

  • Real-world clinical relevance: The study reflects actual surgical practice in a high-volume bariatric center, enhancing the external validity and applicability of the findings to similar settings.

  • Balanced safety analysis: Detailed reporting of both surgical and nutritional complications provides a holistic evaluation of long-term risks associated with each revisional procedure.

Limitations

  • Retrospective design: The retrospective nature limits control over confounders, introduces potential selection bias, and restricts the ability to establish causality.

  • Single-center study: Findings may not be fully generalizable to other institutions with different patient populations, surgical expertise, or postoperative protocols.

  • Non-randomized allocation: Procedure selection was influenced by clinical presentation (e.g., GERD severity, baseline BMI), creating inherent baseline differences between groups that may affect comparative outcomes despite statistical adjustments.

  • Relatively small sample size, especially for subgroup analyses: Although adequate for primary outcomes, the sample limits the statistical power for detecting differences in less frequent complications or comorbidity-specific outcomes.

  • Incomplete long-term nutritional data: While several laboratory markers were assessed, variability in follow-up adherence may have limited the completeness of micronutrient and metabolic assessments at later time points.

  • Absence of patient-reported outcomes: Measures such as quality-of-life, symptom burden, and satisfaction were not evaluated, limiting insight into functional or psychosocial impact.

Source: Strengths and limitations Source: Strengths and limitations

Results

Baseline characteristics

The study examined 105 individuals who returned to surgery after unsuccessful sleeve gastrectomy to perform a revisional bariatric surgery, 62 underwent conversion to RYGB, and 43 were converted from SG to SADI-S. The age of both groups was similar as the mean age of RYGB was 40.66 years, SD 9.47, and that of SADI-S was 39.35 years, SD 9.28 (p = 0.48). But there was significant difference in sex distribution. Females constituted 65.8 percent of the RYGB group and 61.5 percent of the SADI-S group (p = 0.01), indicating that there might be gender-related factors that affect the surgical decision-making [4, 5].

Also, SADI-S patients were revised earlier with an average of 3.53 ± 1.29 years after SG as opposed to 4.13 ± 1.31 years in RYGB patients (p = 0.02). It could be indicative of a rapid weight recurrence regain after SG in subjects who received SADI-S as a revisional conversion surgery (Table 1).

Table 1

Baseline characteristics

VariableRYGB (n = 62)
Mean (SD)
SADI-S (n = 43)
Mean (SD)
P-value
Age (years)40.66 (9.47)39.35 (9.28)0.48
Sex (M/F) n (%)
 F52 (65.8)27 (34.2)0.01*
 M10 (38.5)16 (61.5)
Years from LSG to revision4.13 (1.31)3.53 (1.29)0.02*
Height (cm)162.85 (6.91)165.12 (8.64)0.14
Weight before LSG (kg)128.73 (26.95)141.02 (27.14)0.02*
BMI before LSG (kg/m2)48.15 (8.25)50.40 (11.46)0.24
Lowest weight after LSG (kg)90.07 (18.00)101.84 (21.58)0.005*
Lowest BMI after LSG (kg/m2)33.76 (6.13)32.92 (13.99)0.71
Weight before revisional surgery (kg)107.16 (21.20)119.05 (23.53)0.008*
BMI before revisional surgery (kg/m2)40.22 (6.45)43.51 (7.07)0.01*
ASA score (I: IV)2.15 (0.39)2.12 (0.39)0.7

*F females, M males, LSG laparoscopic sleeve gastrectomy, BMI body mass index, ASA American Society of Anesthesiologists

Anthropometric measurements (Table 1), indicated that SADI-S patients exhibited higher body weight both before SG and prior to revision. Their pre-SG weight was 141.02/27.14 kg on average in comparison to 128.73/26.95 kg in RYGB patients (p = 0.02). Pre-revision weight was also significantly higher in the SADI-S group (119.05 + 23.53 kg) compared with the RYGB group (107.16 + 21.20 kg; p = 0.008). Accordingly, the SADI-S group had a significantly higher pre-revision BMI (43.51 ± 7.07 kg/m2) compared with the RYGB group (40.22 ± 6.45 kg/m2; p = 0.01) [12Not reported14].

Pre-operative comorbidities

The RYGB and SADI-S groups showed comparable preoperative comorbidity profiles (Table 2). The prevalence of diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and asthma did not differ significantly between groups. Diabetes was present in 11 RYGB and 7 SADI-S patients, and hypertension in 11 and 8 patients, respectively, with non-significant p-values. Although dyslipidemia appeared more frequently in the RYGB group (71.4 vs. 28.6%) (Table 2).

Table 2

Co-morbidities pre-op

VariableRYGB
N (%)
SADI-S
N (%)
P-value
Diabetes
 No51 (58.6)36 (41.4)0.84
 Yes11 (61.1)7 (38..9)
Hypertension
 No51 (59.3)35 (40.7)0.9
 Yes11 (57.9)8 (42.1)
Dyslipidaemia
 No52 (57.1)39 (42.9)0.31
 Yes10 (71.4)4 (28.6)
OSA
 No60 (58.3)43 (41.7)0.64
 Yes2 (100.0)0 (0.0)
Asthma
 No55 (57.3)41 (42.7)0.40
 Yes7 (77.8)2 (22.2)
GERD
 No31 (44.3)39 (55.7)0.001*
 Yes31 (88.6)4 (11.4)

*OSA obstructive sleep apnea, GERD gastro-esophageal reflux disease

The only significant difference in preoperative comorbidities was the markedly higher prevalence of GERD among RYGB patients (88.6 vs. 11.4%, p = 0.001). This disparity indicates that GERD was a major determinant in selecting RYGB, consistent with its established efficacy in managing refractory reflux [12]. In contrast, the low prevalence of GERD among SADI-S patients suggests that their revisions were primarily driven by weight-related indications.

Intraoperative and perioperative data

Intraoperative outcomes (Table 3), did not differ significantly between the RYGB and SADI-S groups, indicating comparable procedural efficiency and perioperative safety. Operative time was similar for both procedures, with RYGB averaging 2:00:45 h and SADI-S 2:03:20 h. Length of hospital stay was likewise comparable (3.69 vs. 3.59 days; p = 0.51) (Table 3).

Table 3

Intraoperative data

VariableRYGB (n = 62)SADI-S (n = 43)p-value
Operative time (minutes)2::00:45:00 (0:39 to 03:05)2:03:20:93 (0:30 to 06:65)0.71
Length of hospital stay (days)3.69 (0.87)3.59 (0.74)0.51

Anthropometric outcomes

During the 7-year follow-up, SADI-S consistently achieved superior weight-loss outcomes compared with RYGB (Table 4). Although absolute weight and BMI were similar between groups at each assessment point, SADI-S produced significantly greater reductions in %EWL (53.75 vs. 43.46%, p = 0.05), %TWL (21.63 vs. 15.03%, p = 0.001), and BMI (9.54 vs. 6.07, p < 0.001) at 1 year (Table 4).

Table 4

Anthropometric outcomes comparison of RYGB and SADI-S

RYGB (n = 62)SADI-S (n = 43)P-value
Weight at 1 year89.16 (17.99)93.45 (18.11)0.30
BMI at 1 year33.73 (5.69)34.09 (6.12)0.76
%EWL at 1 year43.46 (27.49)53.75 (22.83)0.05
%TWL at 1 year15.03 (8.43)21.63 (8.25)0.000
BMI reduction at 1 year6.07 (3.44)9.54 (4.08)0.000
Weight at 5 years92.15 (19.27)93.07 (15.58)0.79
BMI at 5 years34.67 (6.00)34.34 (5.85)0.78
%EWL at 5 years34.94 (36.46)49.67 (30.13)0.03
%TWL at 5 years12.49 (10.66)20.52 (12.09)0.001
BMI reduction at 5 years5.13 (4.69)9.27 (6.28)0.000
Weight at 7 years92.17 (21.05)94.89 (16.49)0.49
BMI at 7 years34.64 (6.80)34.73 (5.52)0.94
%EWL at 7 years37.53 (41.24)46.67 (29.36)0.23
%TWL at 7 years13.23 (12.28)19.59 (11.97)0.01
BMI reduction at 7 years5.44 (4.96)8.94 (6.08)0.002

These advantages persisted long-term. At 5 years, SADI-S maintained higher %EWL (49.67 vs. 34.94%, p = 0.03), %TWL (20.52 vs. 12.49%, p = 0.001), and BMI reduction (9.27 vs. 5.13, p < 0.001). By 7 years, absolute weight and BMI were comparable, yet SADI-S continued to show superior %TWL (19.59 vs. 13.23%, p = 0.01) and BMI reduction (8.94 vs. 5.44, p = 0.002). These findings are clearly depicted in Fig. 1.

Fig. 1

Comparative long-term weight loss trajectories after revisional RYGB and SADI-S. Mean percentage excess weight loss (%EWL), percentage total weight loss (%TWL), and body mass index (BMI) reduction are reported at 1, 5, and 7 years after revisional surgery. SADI-S consistently showed higher %EWL and %TWL and greater BMI reduction than RYGB across all follow-up intervals. Values are reported as means with standard deviation. RYGB is shown in orange and SADI-S in green (Color figure online)

Figure image at the original source: open the original paper. This file is not included in this text import.

Collectively, these findings indicate that SADI-S provides more durable and clinically meaningful weight-loss outcomes than RYGB as a revisional surgery after inadequate weight loss following sleeve gastrectomy.

Postoperative laboratory outcomes

Postoperative laboratory assessments (Table 5), at 1, 5, and 7 years demonstrated distinct differences in malabsorption-related parameters between the RYGB and SADI-S groups. Hemoglobin levels remained comparable across all time points. In contrast, calcium levels were consistently lower in the SADI-S group at 5 and 7 years (p = 0.00 and p = 0.04) (Table 5).

Table 5

Post-op lab tests (1, 5, and 7 years) comparison of RYGB and SADI-S

RYGB (n = 62)SADI-S (n = 43)P-Value
Hb_1year11.91 (1.82)11.71 (2.54)0.77
Hb_5year11.78 (1.64)12.07 (2.07)0.43
Hb_7year11.91 (1.77)11.78 (1.31)0.70
Cholesterol_1year4.87 (1.40)4.05 (0.80)0.002*
Cholesterol_5year4.51 (0.93)4.08 (0.77)0.02*
Cholesterol_7year4.65 (0.85)4.21 (0.71)0.01*
TG_1year1.04 (0.49)0.92 (0.53)0.28
TG_5year1.06 (0.52)0.77 (0.24)0.001*
TG_7year0.99 (0.47)0.77 (0.28)0.006*
HDL_1year1.51 (0.37)1.28 (0.29)0.001*
HDL_5year1.55 (0.44)1.33 (0.28)0.007*
HDL_7year1.59 (0.48)1.42 (0.27)0.03*
LDL_Calc_1year2.67 (0.63)2.34 (0.72)0.02*
LDL_Calc_5year2.50 (0.77)2.39 (0.60)0.49
LDL_Calc_7year2.58 (0.69)2.43 (0.62)0.27
Iron_1year10.32 (5.86)12.7 (6.32)0.09
Iron_5year9.29 (4.87)11.51 (6.15)0.10
Iron_7year11.41 (5.96)10.77 (5.32)0.65
HbA1C_1year5.28 (0.60)5.08 (0.40)0.08
HbA1C_5year5.52 (0.65)5.29 (0.53)0.08
HbA1C_7year5.52 (0.71)5.48 (0.69)0.78
Copper_1year17.99 (4.83)15.98 (4.38)0.22
Copper_5year19.10 (3.70)18.21 (5.05)0.59
Copper_7year17.73 (7.87)17.01 (3.93)0.80
Zink_1year10.83 (2.48)9.41 (2.36)0.02*
Zink_5year11.35 (2.19)9.94 (1.53)0.01*
Zink_7year10.61 (1.73)9.51 (1.30)0.04*
Vit D_1year19.49 (10.98)13.90 (7.43)0.005*
Vit D_5year27.92 (23.10)16.43 (10.59)0.02*
Vit D_7year23.79 (13.80)22.11 (10.09)0.52
Ferritin_1year63.66 (149.49)57.15 (64.66)0.83
Ferritin_5year108.19 (203.02)91.47 (184.71)0.71
Ferritin_7year104.15 (238.01)75.51 (120.47)0.55
Folate_1year24.70 (11.59)13.20 (7.71)0.00*
Folate_5year28.42 (12.18)16.52 (12.09)0.01*
Folate_7year27.81 (13.88)14.22 (9.96)0.00*
Vit B12_1year260.69 (136.87)386.53 (282.82)0.01*
Vit B12_5year209.19 (115.39)405.54 (329.00)0.02*
Vit B12_7year256.21 (140.88)465.25 (285.78)0.00*

Lipid profiles showed more pronounced differences. SADI-S patients exhibited significantly lower total cholesterol at 1, 5, and 7 years (p = 0.002, 0.02, and 0.01), and lower triglycerides at 5 and 7 years (p = 0.001 and 0.006), alongside reduced HDL and LDL at all assessments, with LDL reaching statistical significance at 1 year.

Micronutrient evaluation revealed higher zinc and folate levels in RYGB patients. In contrast, vitamin B12 concentrations were consistently higher after SADI-S.

Comorbidity outcomes

Comorbidity outcomes (Table 6) were largely comparable between RYGB and SADI-S, with no statistically significant differences for type 2 diabetes, hypertension, dyslipidemia, or asthma.

Table 6

Comorbidity outcomes comparison of RYGB versus SADI after sleeve gastrectomy

VariableRYGB
N (%)
SADI-S
N (%)
p-value*
Diabetes
 Complete remission or improved4 (44.4)5 (55.6)0.24
 No changes/worse6 (85.7)1 (14.3)
Hypertension
 Complete remission or improved0 (0.0)2 (100.0)0.38
 No changes/worse8 (61.5)5 (38.5)
Dyslipidemia
 Complete remission or improved6 (66..7)3 (33.3)0.99
 No changes/worse2 (50.0)2 (50.0)
Asthma
 Complete remission or improved2 (100.0)0 (0.0)0.99
 No change/worse2 (66.7)1 (33.3)
GERD
 Complete remission or improved19 (95.0)1 (5.0)0.02*

Diabetes remission or improvement occurred in 44.4% of RYGB and 55.6% of SADI-S patients (p = 0.24). Hypertension outcomes were similar overall, with improvement observed only in the SADI-S group (Table 6).

Dyslipidemia remission or improvement was 66.7% in RYGB and 33.3% in SADI-S (p = 0.99).

Asthma improvement rates were low and did not differ between procedures.

In contrast, GERD outcomes favored RYGB: complete remission or improvement occurred in 95.0 versus 5.0% with SADI-S (p = 0.02), and persistent or progressive GERD was more common after SADI-S.

Postoperative complications

Postoperative complications (Table 7) were uncommon in both groups, and no statistically significant differences were observed between RYGB and SADI-S. Bleeding occurred in one RYGB patient and in none of the SADI-S patients (p = 0.99). Marginal ulceration was reported more frequently after RYGB, though not significantly so (p = 0.61). Internal hernia occurred only in the RYGB group (two cases), but this difference was also not significant (p = 0.64). Dumping syndrome was more frequently reported after RYGB (81.8 vs. 18.2%), although the difference did not reach statistical significance (p = 0.19) (Table 7).

Table 7

Comparison of complications outcomes following RYGB versus SADI-S

VariableRYGB n (%)SADI-S n (%)p-value
Bleeding
 Yes1 (100)0 (0.0)0.99
 No61 (58.7)43 (41.3)
Marginal ulcer
 Yes4 (80.0)1 (25.0)0.61
 No58 (58.0)42 (42.0)
Internal Hernia
 Yes2 (100.0)0 (0.0)0.64
 No60 (58.3)43 (41.7)
Dumping syndrome
 Yes9 (81.8)2 (18.2)0.19
 No53 (56.4)41 (43.6)
Vitamin deficiencies
 Yes18 (62.1)11 (37.9)0.69
 No44 (57.9)32 (42.1)
Severe malnutrition
 Yes1 (33.3)2 (66.7)0.74
 No61 (59.8)41 (40.2)
IDA
 Yes27 (55.1)22 (44.9)0.44
 No35 (52.5)21 37.5)

*IDA iron deficiency anemia

Nutritional and metabolic complications showed similar patterns between procedures. Vitamin deficiencies were observed in 62.1% of RYGB and 37.9% of SADI-S patients (p = 0.69). Severe malnutrition was rare, occurring in one RYGB and two SADI-S patients (p = 0.74). Iron-deficiency anemia was common in both cohorts: 55.1% in RYGB and 44.9% in SADI-S: with no significant difference (p = 0.44).

Notably, neither group experienced anastomotic leak, bowel obstruction, or stricture.

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusions

This 7-year comparative analysis demonstrates that both Roux-en-Y gastric bypass and single-anastomosis duodeno-ileal bypass are effective and safe revisional procedures for inadequate weight loss after sleeve gastrectomy. Both operations produced durable long-term weight reduction with acceptable complication rates when supported by structured follow-up and nutritional monitoring.

However, clinically meaningful differences were evident. SADI-S yielded superior long-term weight-loss outcomes, reflected in higher total and excess weight loss and greater BMI reduction at 1, 5, and 7 years. These findings highlight the stronger malabsorptive effect of SADI-S, particularly benefiting patients with higher pre-revisional weight or significant weight regain after sleeve gastrectomy.

In contrast, RYGB demonstrated a clear advantage in managing gastroesophageal reflux disease, achieving substantially higher rates of symptom resolution. Outcomes related to other obesity-associated comorbidities, including diabetes and hypertension, were similar between procedures. Although nutritional parameters differed, severe malnutrition and major surgical complications remained infrequent in both groups.

Overall, these results support a personalized approach to revisional bariatric surgery, balancing long-term weight-loss goals, symptom control, and nutritional risk. Lifelong follow-up remains essential to optimize outcomes and sustain the benefits of either revisional strategy.

Source: Conclusions Source: Conclusions Source: Conclusions Source: Conclusions
Authors’ abstract

Background

Sleeve gastrectomy (SG) is widely performed, yet 20 to 50% of patients experience insufficient weight loss or weight regain, leading to revisional surgery. Roux-en-Y gastric bypass (RYGB) and single-anastomosis duodeno-ileal bypass (SADI-S) are two commonly used revisional procedures, but long-term comparative data remain limited. This study evaluates 7-year outcomes of RYGB versus SADI-S as revisional surgeries for weight recurrence after SG.

Methods

A retrospective analysis was conducted on all adults undergoing revisional RYGB or SADI-S between 2014 and 2015 after inadequate weight loss or weight recurrence post-SG. Demographic, anthropometric, biochemical, and comorbidity-related variables were assessed at baseline, 1, 5, and 7 years. Statistical analyses included t-tests, chi-square tests, Kaplan: Meier curves, and multivariate regression (significance set at p < 0.05).

Results

The cohort included 105 patients (RYGB = 62; SADI-S = 43). SADI-S patients had higher baseline and pre-revision BMI. Across all follow-up points, SADI-S achieved significantly greater %TWL, %EWL, and BMI reduction, demonstrating superior long-term weight-loss durability. RYGB yielded markedly better GERD resolution (95 vs. 5%, p = 0.02), while remission of diabetes, hypertension, dyslipidemia, and asthma was similar between groups. Nutritional profiles differed: SADI-S was associated with lower calcium, zinc, folate, and vitamin D levels, whereas RYGB patients had lower vitamin B12.

Overall complication rates, including bleeding, marginal ulcer, internal hernia, dumping syndrome, severe malnutrition, and iron-deficiency anemia, were not statistically significant.

Conclusions

Both RYGB and SADI-S are effective and safe revisional options after SG. SADI-S offers superior long-term weight-loss and metabolic outcomes, whereas RYGB remains preferable for patients with significant or persistent GERD. Tailoring revisional procedure selection to patient characteristics and ensuring lifelong nutritional monitoring are essential for optimizing long-term outcomes.

Read the full paper

Obesity continues to represent a major global health challenge, with rising prevalence and substantial clinical and economic burden. Bariatric surgery remains the most effective long-term treatment for severe obesity, consistently outperforming nonsurgical interventions in sustained weight reduction and comorbidity improvement. Among surgical options, sleeve gastrectomy (SG) has become the predominant primary procedure due to its technical simplicity, favorable safety profile, and reliable early outcomes [1, 2]. Despite these advantages, 20 to 50% of SG patients experience inadequate weight loss, significant weight regain, or complications such as severe gastroesophageal reflux disease (GERD), ultimately necessitating revisional surgery [3Not reported5].

Roux-en-Y gastric bypass (RYGB) has long served as the standard revisional procedure, particularly for patients with refractory GERD. More recently, single-anastomosis duodeno-ileal bypass (SADI-S) has gained attention for its technical feasibility and robust metabolic impact [6]. However, while both procedures have become widely adopted, comparative long-term data: especially beyond five years: remain insufficient. This gap is clinically relevant, as obesity is a chronic and relapsing disease, requiring extended or even lifelong follow-up to fully characterize the durability of revisional outcomes [6].

In practice, the choice of revisional procedure is often influenced by the patient’s main complaint. For example, patients who mainly complain of weight recurrence are offered a more malabsorptive procedure; however, those who mainly complain of severe GERD symptoms are usually offered Roux-en-Y gastric bypass. This highlights the importance of evaluating both weight-related and symptom-specific outcomes when comparing revisional strategies [7, 8].

Although both procedures, RYGB and SADI-S, demonstrated effectiveness as revisional procedures, their long-term results regarding weight loss durability, GERD symptom control, and comorbidity resolution beyond five years remain less well defined.

Nutritional safety remains central for the choice of revisional surgery. SADI-S, with its long biliopancreatic limb, raises concerns about micronutrient deficiencies and bone health, whereas RYGB has its own spectrum of nutritional complications. This also raises the need for long-term comparative data to balance efficacy against nutritional safety. Given the increasing use of revisional bariatric surgery and the limited availability of long-term comparative data, this study provides important insights into the differential benefits and risks of RYGB and SADI-S. By integrating 7-year anthropometric, metabolic, and symptom-specific outcomes, this work supports a more individualized and evidence-based approach to procedure selection [7, 9].

Methods

This retrospective cohort study compared the long-term outcomes in patients undergoing revisional bariatric surgery after insufficient weight loss after sleeve gastrectomy (SG) or weight recurrence. Suboptimal outcomes after sleeve gastrectomy were defined according to accepted international standards as either insufficient weight loss: defined as a percentage of total weight loss (%TWL) of less than 20% and/or a percentage of excess weight loss (%EWL) of less than 50% at 18 to 24 months postoperatively: or significant weight regain following an initial satisfactory weight loss response [10, 11].

The study included all adult patients who underwent either RYGB or SADI-S at our institution between January 1, 2014, and December 31, 2015. The insufficient weight loss or severe weight recurrence regain was to be revised according to the clinical standards of failed SG. Patients were excluded if they received a revisional operation other than RYGB or SADI-S, if revision was performed solely for non-weight-related complications such as GERD or stricture, or if they did not follow-up adequately after the operation.

A total of 105 patients met the inclusion criteria and were included: 62 RYGB and 43 SADI-S patients.

Surgical technique

All procedures were performed as revisional laparoscopic procedures after SG, and none were converted to open procedures.

RYGB: The Roux-en-Y gastric bypass was performed using a standardized technique. A small gastric pouch (30 to 50 ml) was fashioned by transecting the previously sleeved stomach approximately 4 cm distal to the gastroesophageal junction with additional trimming performed when necessary to optimize pouch configuration. The alimentary (Roux) limb was constructed with a length of 100 cm, and the biliopancreatic limb measured 125 cm. Both Petersen’s space and the mesenteric defect at the jejunojejunostomy were systematically closed to minimize the risk of internal herniation.

No intra-abdominal drains were routinely placed.

SADI-S: After inspection of the abdominal cavity, a retropyloric-retroduodenal dissection was carried out to expose approximately 3 cm of the duodenum distal to the pylorus, which was then transected. The small bowel length was measured from the ileocecal junction, and a 300-cm ileal common channel was constructed. A double layer end: to: side duodeno-ileal anastomosis was created in an isoperistaltic fashion. No intra-abdominal drains were routinely placed.

Demographic and baseline clinical data were obtained from electronic medical records. The variables included age, sex, height, weight prior to SG, nadir weight after SG, and weight prior to revisional surgery. Comorbidity data were collected and classified as diabetes, hypertension, dyslipidemia, asthma, obstructive sleep apnea, and GERD.

Perioperative variables, including operative time and length of stay, were also extracted. Laboratory markers, including hemoglobin, micronutrients, lipid profile, ferritin, folate, vitamin B12, and vitamin D, were recorded at baseline, 1, 5, and 7 years to assess nutritional status at later time points.

At 1-, 5-, and 7-year post-revision follow-up, anthropometric measurements were obtained. Variables included body weight, BMI, percentage excess weight loss (percent EWL), percentage total weight loss (percent TWL), and body weight reduction.

All complications after the operation, such as bleeding, internal hernia, marginal ulcers, dumping syndrome, severe malnutrition, vitamin deficiencies, and iron deficiency anemia, were carefully reviewed through electronic records from surgery to the date of data collection.

The SPSS version 26 was used to perform statistical analysis. Independent samples based on distributions (either independent-sample t-tests or Mann Whitey U tests). Chi-square test or Fisher exact test was used to analyze categorical variables. Kaplan Meier curves were used to determine time-to-event data (e.g., complication-free survival), whereas Cox proportional hazards techniques were employed to estimate outcome predictors. A p-value < 0.05 was considered statistically significant.

Results

Baseline characteristics

The study examined 105 individuals who returned to surgery after unsuccessful sleeve gastrectomy to perform a revisional bariatric surgery, 62 underwent conversion to RYGB, and 43 were converted from SG to SADI-S. The age of both groups was similar as the mean age of RYGB was 40.66 years, SD 9.47, and that of SADI-S was 39.35 years, SD 9.28 (p = 0.48). But there was significant difference in sex distribution. Females constituted 65.8 percent of the RYGB group and 61.5 percent of the SADI-S group (p = 0.01), indicating that there might be gender-related factors that affect the surgical decision-making [4, 5].

Also, SADI-S patients were revised earlier with an average of 3.53 ± 1.29 years after SG as opposed to 4.13 ± 1.31 years in RYGB patients (p = 0.02). It could be indicative of a rapid weight recurrence regain after SG in subjects who received SADI-S as a revisional conversion surgery (Table 1).

Table 1

Baseline characteristics

VariableRYGB (n = 62)
Mean (SD)
SADI-S (n = 43)
Mean (SD)
P-value
Age (years)40.66 (9.47)39.35 (9.28)0.48
Sex (M/F) n (%)
 F52 (65.8)27 (34.2)0.01*
 M10 (38.5)16 (61.5)
Years from LSG to revision4.13 (1.31)3.53 (1.29)0.02*
Height (cm)162.85 (6.91)165.12 (8.64)0.14
Weight before LSG (kg)128.73 (26.95)141.02 (27.14)0.02*
BMI before LSG (kg/m2)48.15 (8.25)50.40 (11.46)0.24
Lowest weight after LSG (kg)90.07 (18.00)101.84 (21.58)0.005*
Lowest BMI after LSG (kg/m2)33.76 (6.13)32.92 (13.99)0.71
Weight before revisional surgery (kg)107.16 (21.20)119.05 (23.53)0.008*
BMI before revisional surgery (kg/m2)40.22 (6.45)43.51 (7.07)0.01*
ASA score (I: IV)2.15 (0.39)2.12 (0.39)0.7

*F females, M males, LSG laparoscopic sleeve gastrectomy, BMI body mass index, ASA American Society of Anesthesiologists

Anthropometric measurements (Table 1), indicated that SADI-S patients exhibited higher body weight both before SG and prior to revision. Their pre-SG weight was 141.02/27.14 kg on average in comparison to 128.73/26.95 kg in RYGB patients (p = 0.02). Pre-revision weight was also significantly higher in the SADI-S group (119.05 + 23.53 kg) compared with the RYGB group (107.16 + 21.20 kg; p = 0.008). Accordingly, the SADI-S group had a significantly higher pre-revision BMI (43.51 ± 7.07 kg/m2) compared with the RYGB group (40.22 ± 6.45 kg/m2; p = 0.01) [12Not reported14].

Pre-operative comorbidities

The RYGB and SADI-S groups showed comparable preoperative comorbidity profiles (Table 2). The prevalence of diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and asthma did not differ significantly between groups. Diabetes was present in 11 RYGB and 7 SADI-S patients, and hypertension in 11 and 8 patients, respectively, with non-significant p-values. Although dyslipidemia appeared more frequently in the RYGB group (71.4 vs. 28.6%) (Table 2).

Table 2

Co-morbidities pre-op

VariableRYGB
N (%)
SADI-S
N (%)
P-value
Diabetes
 No51 (58.6)36 (41.4)0.84
 Yes11 (61.1)7 (38..9)
Hypertension
 No51 (59.3)35 (40.7)0.9
 Yes11 (57.9)8 (42.1)
Dyslipidaemia
 No52 (57.1)39 (42.9)0.31
 Yes10 (71.4)4 (28.6)
OSA
 No60 (58.3)43 (41.7)0.64
 Yes2 (100.0)0 (0.0)
Asthma
 No55 (57.3)41 (42.7)0.40
 Yes7 (77.8)2 (22.2)
GERD
 No31 (44.3)39 (55.7)0.001*
 Yes31 (88.6)4 (11.4)

*OSA obstructive sleep apnea, GERD gastro-esophageal reflux disease

The only significant difference in preoperative comorbidities was the markedly higher prevalence of GERD among RYGB patients (88.6 vs. 11.4%, p = 0.001). This disparity indicates that GERD was a major determinant in selecting RYGB, consistent with its established efficacy in managing refractory reflux [12]. In contrast, the low prevalence of GERD among SADI-S patients suggests that their revisions were primarily driven by weight-related indications.

Intraoperative and perioperative data

Intraoperative outcomes (Table 3), did not differ significantly between the RYGB and SADI-S groups, indicating comparable procedural efficiency and perioperative safety. Operative time was similar for both procedures, with RYGB averaging 2:00:45 h and SADI-S 2:03:20 h. Length of hospital stay was likewise comparable (3.69 vs. 3.59 days; p = 0.51) (Table 3).

Table 3

Intraoperative data

VariableRYGB (n = 62)SADI-S (n = 43)p-value
Operative time (minutes)2::00:45:00 (0:39 to 03:05)2:03:20:93 (0:30 to 06:65)0.71
Length of hospital stay (days)3.69 (0.87)3.59 (0.74)0.51

Anthropometric outcomes

During the 7-year follow-up, SADI-S consistently achieved superior weight-loss outcomes compared with RYGB (Table 4). Although absolute weight and BMI were similar between groups at each assessment point, SADI-S produced significantly greater reductions in %EWL (53.75 vs. 43.46%, p = 0.05), %TWL (21.63 vs. 15.03%, p = 0.001), and BMI (9.54 vs. 6.07, p < 0.001) at 1 year (Table 4).

Table 4

Anthropometric outcomes comparison of RYGB and SADI-S

RYGB (n = 62)SADI-S (n = 43)P-value
Weight at 1 year89.16 (17.99)93.45 (18.11)0.30
BMI at 1 year33.73 (5.69)34.09 (6.12)0.76
%EWL at 1 year43.46 (27.49)53.75 (22.83)0.05
%TWL at 1 year15.03 (8.43)21.63 (8.25)0.000
BMI reduction at 1 year6.07 (3.44)9.54 (4.08)0.000
Weight at 5 years92.15 (19.27)93.07 (15.58)0.79
BMI at 5 years34.67 (6.00)34.34 (5.85)0.78
%EWL at 5 years34.94 (36.46)49.67 (30.13)0.03
%TWL at 5 years12.49 (10.66)20.52 (12.09)0.001
BMI reduction at 5 years5.13 (4.69)9.27 (6.28)0.000
Weight at 7 years92.17 (21.05)94.89 (16.49)0.49
BMI at 7 years34.64 (6.80)34.73 (5.52)0.94
%EWL at 7 years37.53 (41.24)46.67 (29.36)0.23
%TWL at 7 years13.23 (12.28)19.59 (11.97)0.01
BMI reduction at 7 years5.44 (4.96)8.94 (6.08)0.002

These advantages persisted long-term. At 5 years, SADI-S maintained higher %EWL (49.67 vs. 34.94%, p = 0.03), %TWL (20.52 vs. 12.49%, p = 0.001), and BMI reduction (9.27 vs. 5.13, p < 0.001). By 7 years, absolute weight and BMI were comparable, yet SADI-S continued to show superior %TWL (19.59 vs. 13.23%, p = 0.01) and BMI reduction (8.94 vs. 5.44, p = 0.002). These findings are clearly depicted in Fig. 1.

Fig. 1

Comparative long-term weight loss trajectories after revisional RYGB and SADI-S. Mean percentage excess weight loss (%EWL), percentage total weight loss (%TWL), and body mass index (BMI) reduction are reported at 1, 5, and 7 years after revisional surgery. SADI-S consistently showed higher %EWL and %TWL and greater BMI reduction than RYGB across all follow-up intervals. Values are reported as means with standard deviation. RYGB is shown in orange and SADI-S in green (Color figure online)

Figure image at the original source: open the original paper. This file is not included in this text import.

Collectively, these findings indicate that SADI-S provides more durable and clinically meaningful weight-loss outcomes than RYGB as a revisional surgery after inadequate weight loss following sleeve gastrectomy.

Postoperative laboratory outcomes

Postoperative laboratory assessments (Table 5), at 1, 5, and 7 years demonstrated distinct differences in malabsorption-related parameters between the RYGB and SADI-S groups. Hemoglobin levels remained comparable across all time points. In contrast, calcium levels were consistently lower in the SADI-S group at 5 and 7 years (p = 0.00 and p = 0.04) (Table 5).

Table 5

Post-op lab tests (1, 5, and 7 years) comparison of RYGB and SADI-S

RYGB (n = 62)SADI-S (n = 43)P-Value
Hb_1year11.91 (1.82)11.71 (2.54)0.77
Hb_5year11.78 (1.64)12.07 (2.07)0.43
Hb_7year11.91 (1.77)11.78 (1.31)0.70
Cholesterol_1year4.87 (1.40)4.05 (0.80)0.002*
Cholesterol_5year4.51 (0.93)4.08 (0.77)0.02*
Cholesterol_7year4.65 (0.85)4.21 (0.71)0.01*
TG_1year1.04 (0.49)0.92 (0.53)0.28
TG_5year1.06 (0.52)0.77 (0.24)0.001*
TG_7year0.99 (0.47)0.77 (0.28)0.006*
HDL_1year1.51 (0.37)1.28 (0.29)0.001*
HDL_5year1.55 (0.44)1.33 (0.28)0.007*
HDL_7year1.59 (0.48)1.42 (0.27)0.03*
LDL_Calc_1year2.67 (0.63)2.34 (0.72)0.02*
LDL_Calc_5year2.50 (0.77)2.39 (0.60)0.49
LDL_Calc_7year2.58 (0.69)2.43 (0.62)0.27
Iron_1year10.32 (5.86)12.7 (6.32)0.09
Iron_5year9.29 (4.87)11.51 (6.15)0.10
Iron_7year11.41 (5.96)10.77 (5.32)0.65
HbA1C_1year5.28 (0.60)5.08 (0.40)0.08
HbA1C_5year5.52 (0.65)5.29 (0.53)0.08
HbA1C_7year5.52 (0.71)5.48 (0.69)0.78
Copper_1year17.99 (4.83)15.98 (4.38)0.22
Copper_5year19.10 (3.70)18.21 (5.05)0.59
Copper_7year17.73 (7.87)17.01 (3.93)0.80
Zink_1year10.83 (2.48)9.41 (2.36)0.02*
Zink_5year11.35 (2.19)9.94 (1.53)0.01*
Zink_7year10.61 (1.73)9.51 (1.30)0.04*
Vit D_1year19.49 (10.98)13.90 (7.43)0.005*
Vit D_5year27.92 (23.10)16.43 (10.59)0.02*
Vit D_7year23.79 (13.80)22.11 (10.09)0.52
Ferritin_1year63.66 (149.49)57.15 (64.66)0.83
Ferritin_5year108.19 (203.02)91.47 (184.71)0.71
Ferritin_7year104.15 (238.01)75.51 (120.47)0.55
Folate_1year24.70 (11.59)13.20 (7.71)0.00*
Folate_5year28.42 (12.18)16.52 (12.09)0.01*
Folate_7year27.81 (13.88)14.22 (9.96)0.00*
Vit B12_1year260.69 (136.87)386.53 (282.82)0.01*
Vit B12_5year209.19 (115.39)405.54 (329.00)0.02*
Vit B12_7year256.21 (140.88)465.25 (285.78)0.00*

Lipid profiles showed more pronounced differences. SADI-S patients exhibited significantly lower total cholesterol at 1, 5, and 7 years (p = 0.002, 0.02, and 0.01), and lower triglycerides at 5 and 7 years (p = 0.001 and 0.006), alongside reduced HDL and LDL at all assessments, with LDL reaching statistical significance at 1 year.

Micronutrient evaluation revealed higher zinc and folate levels in RYGB patients. In contrast, vitamin B12 concentrations were consistently higher after SADI-S.

Comorbidity outcomes

Comorbidity outcomes (Table 6) were largely comparable between RYGB and SADI-S, with no statistically significant differences for type 2 diabetes, hypertension, dyslipidemia, or asthma.

Table 6

Comorbidity outcomes comparison of RYGB versus SADI after sleeve gastrectomy

VariableRYGB
N (%)
SADI-S
N (%)
p-value*
Diabetes
 Complete remission or improved4 (44.4)5 (55.6)0.24
 No changes/worse6 (85.7)1 (14.3)
Hypertension
 Complete remission or improved0 (0.0)2 (100.0)0.38
 No changes/worse8 (61.5)5 (38.5)
Dyslipidemia
 Complete remission or improved6 (66..7)3 (33.3)0.99
 No changes/worse2 (50.0)2 (50.0)
Asthma
 Complete remission or improved2 (100.0)0 (0.0)0.99
 No change/worse2 (66.7)1 (33.3)
GERD
 Complete remission or improved19 (95.0)1 (5.0)0.02*

Diabetes remission or improvement occurred in 44.4% of RYGB and 55.6% of SADI-S patients (p = 0.24). Hypertension outcomes were similar overall, with improvement observed only in the SADI-S group (Table 6).

Dyslipidemia remission or improvement was 66.7% in RYGB and 33.3% in SADI-S (p = 0.99).

Asthma improvement rates were low and did not differ between procedures.

In contrast, GERD outcomes favored RYGB: complete remission or improvement occurred in 95.0 versus 5.0% with SADI-S (p = 0.02), and persistent or progressive GERD was more common after SADI-S.

Postoperative complications

Postoperative complications (Table 7) were uncommon in both groups, and no statistically significant differences were observed between RYGB and SADI-S. Bleeding occurred in one RYGB patient and in none of the SADI-S patients (p = 0.99). Marginal ulceration was reported more frequently after RYGB, though not significantly so (p = 0.61). Internal hernia occurred only in the RYGB group (two cases), but this difference was also not significant (p = 0.64). Dumping syndrome was more frequently reported after RYGB (81.8 vs. 18.2%), although the difference did not reach statistical significance (p = 0.19) (Table 7).

Table 7

Comparison of complications outcomes following RYGB versus SADI-S

VariableRYGB n (%)SADI-S n (%)p-value
Bleeding
 Yes1 (100)0 (0.0)0.99
 No61 (58.7)43 (41.3)
Marginal ulcer
 Yes4 (80.0)1 (25.0)0.61
 No58 (58.0)42 (42.0)
Internal Hernia
 Yes2 (100.0)0 (0.0)0.64
 No60 (58.3)43 (41.7)
Dumping syndrome
 Yes9 (81.8)2 (18.2)0.19
 No53 (56.4)41 (43.6)
Vitamin deficiencies
 Yes18 (62.1)11 (37.9)0.69
 No44 (57.9)32 (42.1)
Severe malnutrition
 Yes1 (33.3)2 (66.7)0.74
 No61 (59.8)41 (40.2)
IDA
 Yes27 (55.1)22 (44.9)0.44
 No35 (52.5)21 37.5)

*IDA iron deficiency anemia

Nutritional and metabolic complications showed similar patterns between procedures. Vitamin deficiencies were observed in 62.1% of RYGB and 37.9% of SADI-S patients (p = 0.69). Severe malnutrition was rare, occurring in one RYGB and two SADI-S patients (p = 0.74). Iron-deficiency anemia was common in both cohorts: 55.1% in RYGB and 44.9% in SADI-S: with no significant difference (p = 0.44).

Notably, neither group experienced anastomotic leak, bowel obstruction, or stricture.

Discussion

Long-term weight loss outcomes

Current evidence indicates that both Roux-en-Y gastric bypass (RYGB) and single-anastomosis duodeno-ileal bypass (SADI-S) are effective revisional procedures following inadequate weight loss after sleeve gastrectomy. However, SADI-S consistently demonstrates superior long-term weight-loss outcomes. Patients undergoing SADI-S achieve significantly greater percentages of excess weight loss (EWL), total weight loss (TWL), and BMI reduction at 1, 5, and 7 years, reflecting more durable weight-loss maintenance [3, 6].

This enhanced effect is likely attributable to the greater malabsorptive component of SADI-S, driven by duodenal diversion and a longer bypassed intestinal segment, which augments long-term metabolic and caloric malabsorption. Such characteristics may be particularly advantageous in patients with higher pre-revision BMI or early failure after sleeve gastrectomy. By contrast, although RYGB produces meaningful weight loss, its mixed restrictive-malabsorptive mechanism may offer comparatively less sustained benefit in higher-BMI revisional populations [6, 13, 15].

Resolution of obesity-related comorbidities

Both revisional procedures achieved comparable improvement or remission of obesity-related comorbidities: including type 2 diabetes, hypertension, dyslipidemia, and asthma: with no statistically significant differences between RYGB and SADI-S. These findings suggest that weight loss itself is the principal driver of metabolic improvement before and after revision, regardless of the surgical technique [12, 13].

However, the outcomes for gastroesophageal reflux disease (GERD) differed markedly between procedures. RYGB resulted in significantly higher rates of GERD remission or improvement, consistent with its well-established anti-reflux mechanism that diverts both gastric acid and bile from the esophagus. These results reaffirm RYGB as the preferred revisional option for patients presenting with severe or persistent GERD after sleeve gastrectomy [16].

Perioperative and short-term safety outcomes

Operative time and length of hospital stay did not differ significantly between the groups, indicating comparable perioperative efficiency and safety for both RYGB and SADI-S. These findings support the feasibility of performing either procedure as a revisional intervention in experienced bariatric centers. The similarity in early postoperative recovery further reinforces SADI-S as a viable revisional procedure [6, 14].

Early postoperative complications were also comparable. Neither cohort experienced anastomotic leak, bowel obstruction, or stricture, and no significant differences were observed in other early surgical events. These results underscore that, with appropriate patient selection and surgical expertise, revisional bariatric procedures can be performed with low perioperative risk despite the inherent complexity of re-operative surgery [13, 17].

Nutritional and metabolic outcomes

Long-term laboratory follow-up showed that most nutritional parameters: including hemoglobin, albumin, and total protein: remained comparable between the two groups throughout the study period. In contrast, differences emerged in lipid profiles and selected micronutrients. SADI-S patients demonstrated greater reductions in total cholesterol and triglycerides over time, reflecting the more pronounced metabolic effects of this procedure [3, 5, 18, 19].

Both procedures were associated with persistent micronutrient deficiencies, particularly in iron, vitamin D, zinc, folate, and vitamin B12. Although severe malnutrition was rare, these findings underscore the need for lifelong nutritional monitoring after revisional surgery. The greater malabsorptive component of SADI-S, in particular, necessitates strict adherence to postoperative supplementation to mitigate long-term deficiency risks [6, 20, 21].

Postoperative complications and long-term safety

Overall complication rates were low and did not differ significantly between RYGB and SADI-S, with no meaningful variation in bleeding, marginal ulceration, internal hernia, dumping syndrome, or iron-deficiency anemia. These findings indicate that both procedures share comparable safety profiles when performed in appropriately selected patients.

Severe malnutrition was uncommon in both cohorts, further supporting the long-term safety of these revisional procedures. However, the persistence of micronutrient deficiencies underscores the chronic nutritional risks inherent to malabsorptive procedures. These results highlight the importance of structured postoperative follow-up and strict adherence to supplementation to sustain long-term outcomes after revision [5, 22].

Clinical implications and procedure selection

This study demonstrates that RYGB and SADI-S serve complementary roles rather than interchangeable ones in revisional bariatric surgery. SADI-S offers superior long-term weight-loss durability and metabolic benefits, making it particularly suitable for patients with higher-BMI or early post-sleeve gastrectomy failure. In contrast, RYGB offers a clear advantage in managing GERD and is the preferred option for patients presenting with reflux-dominant symptoms [3, 5, 23].

Accordingly, selection of the revisional procedure should be individualized, integrating factors such as baseline BMI, presence of GERD, nutritional risk, and the patient’s capacity for long-term follow-up. Shared decision-making between the surgeon and the patient remains essential for optimizing outcomes and minimizing postoperative complications [16, 22].

Conclusions

This 7-year comparative analysis demonstrates that both Roux-en-Y gastric bypass and single-anastomosis duodeno-ileal bypass are effective and safe revisional procedures for inadequate weight loss after sleeve gastrectomy. Both operations produced durable long-term weight reduction with acceptable complication rates when supported by structured follow-up and nutritional monitoring.

However, clinically meaningful differences were evident. SADI-S yielded superior long-term weight-loss outcomes, reflected in higher total and excess weight loss and greater BMI reduction at 1, 5, and 7 years. These findings highlight the stronger malabsorptive effect of SADI-S, particularly benefiting patients with higher pre-revisional weight or significant weight regain after sleeve gastrectomy.

In contrast, RYGB demonstrated a clear advantage in managing gastroesophageal reflux disease, achieving substantially higher rates of symptom resolution. Outcomes related to other obesity-associated comorbidities, including diabetes and hypertension, were similar between procedures. Although nutritional parameters differed, severe malnutrition and major surgical complications remained infrequent in both groups.

Overall, these results support a personalized approach to revisional bariatric surgery, balancing long-term weight-loss goals, symptom control, and nutritional risk. Lifelong follow-up remains essential to optimize outcomes and sustain the benefits of either revisional strategy.

Strengths and limitations

Strengths

  • Long-term follow-up: The study provides 7-year outcomes, offering rare long-term comparative data on RYGB and SADI-S as revisional procedures: a time horizon seldom reported in the literature.

  • Direct comparison of two major revisional techniques: The analysis contrasts two of the most commonly performed revisional operations after failed sleeve gastrectomy, enabling meaningful clinical comparisons in weight-loss durability, metabolic outcomes, and safety.

  • Comprehensive clinical assessment: Anthropometric, biochemical, metabolic, and comorbidity-related data were systematically collected at multiple time points (baseline, 1, 5, and 7 years), strengthening the robustness of outcome evaluation.

  • Real-world clinical relevance: The study reflects actual surgical practice in a high-volume bariatric center, enhancing the external validity and applicability of the findings to similar settings.

  • Balanced safety analysis: Detailed reporting of both surgical and nutritional complications provides a holistic evaluation of long-term risks associated with each revisional procedure.

Limitations

  • Retrospective design: The retrospective nature limits control over confounders, introduces potential selection bias, and restricts the ability to establish causality.

  • Single-center study: Findings may not be fully generalizable to other institutions with different patient populations, surgical expertise, or postoperative protocols.

  • Non-randomized allocation: Procedure selection was influenced by clinical presentation (e.g., GERD severity, baseline BMI), creating inherent baseline differences between groups that may affect comparative outcomes despite statistical adjustments.

  • Relatively small sample size, especially for subgroup analyses: Although adequate for primary outcomes, the sample limits the statistical power for detecting differences in less frequent complications or comorbidity-specific outcomes.

  • Incomplete long-term nutritional data: While several laboratory markers were assessed, variability in follow-up adherence may have limited the completeness of micronutrient and metabolic assessments at later time points.

  • Absence of patient-reported outcomes: Measures such as quality-of-life, symptom burden, and satisfaction were not evaluated, limiting insight into functional or psychosocial impact.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Funding

Open Access funding provided by the Qatar National Library. No funding was received for the conduct of this study or the preparation of this manuscript.

Declarations

Disclosure

Drs. Asaad Salama, Abdelwahed Yahmadi, Hamzah El Baba, Jawher Baazaoui, Khadija Gibreal, Mohamed Bougmiza and Mohammed Al Kuwari have no conflicts of interest or financial ties to disclose.

Ethical approval

The institutional review board of Hamad Medical Corporation (HMC) had granted ethical approval for this retrospective study, and the study's conduct followed the principles of the Declaration of Helsinki. Since this was a retrospective review of existing records, individual informed consent was no longer required.

References

1. Salas-Parra RD, Smolkin C, Choksi S, Pryor AD (2024) Bariatric surgery: current trends and newer surgeries. Gastrointest Endosc Clin N Am 34(4):609 to 626 (PMID: 39277294) 39277294 10.1016/j.giec.2024.06.005
2. Leslie D, Wise E, Sheka A, Abdelwahab H, Irey R, Benner A, Ikramuddin S (2021) Gastroesophageal reflux disease outcomes after vertical sleeve gastrectomy and gastric bypass. Ann Surg 274(4):646 to 653 (PMID: 34506320) 34506320 10.1097/SLA.0000000000005061
3. Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Mazzini G, Pereira Mda S (2016) The impact of gastric bypass on gastroesophageal reflux disease in morbidly obese patients. Ann Surg 263(1):110 to 116 (PMID: 25607766) 25607766 10.1097/SLA.0000000000001139
4. Benamran D, Chierici A, Temime V, Drai C, Iannelli A (2024) Results of sleeve gastrectomy conversion to Roux-en-Y gastric bypass on gastroesophageal reflux disease symptoms and proton pump inhibitors use evolution over time. J Gastrointest Surg 28(9):1412 to 1419 (PMID: 38852930) 38852930 10.1016/j.gassur.2024.06.001
5. Shen MR, Hammoud MM, Bonham AJ, Aaron B, Ghaferi AA, Varban OA, Carlin AM, Ehlers AP, Finks JF (2024) Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: impact on reflux and weight loss. Surg Obes Relat Dis 20(8):738 to 744 (PMCID: PMC11472848) 38704333 10.1016/j.soard.2024.04.001 PMC11472848
6. Vaz M, Pereira SS, Monteiro MP (2022) Metabolomic signatures after bariatric surgery: a systematic review. Rev Endocr Metab Disord 23(3):503 to 519 (PMCID: PMC9156502) 34855133 10.1007/s11154-021-09695-5 PMC9156502
7. Dijkhorst PJ, Al Nawas M, Heusschen L, Hazebroek EJ, Swank DJ, Wiezer RMJ, Aarts EO (2021) Single anastomosis duodenoileal bypass or Roux-en-Y gastric bypass after failed sleeve gastrectomy: medium-term outcomes. Obes Surg 31(11):4708 to 4716 34398380 10.1007/s11695-021-05609-1 PMC8490218
8. Thomopoulos T, Mantziari S, Joliat GR (2024) Long-term results of Roux-en-Y gastric bypass (RYGB) versus single anastomosis duodeno-ileal bypass (SADI) as revisional procedures after failed sleeve gastrectomy: a systematic literature review and pooled analysis. Langenbecks Arch Surg 409(1):354 39579238 10.1007/s00423-024-03557-9 PMC11585492
9. El-Masry H, Mahmoud MH, Mohamed BS, Elraggal D, Elkholy MH, Abokhozima A (2025) The nutritional challenges following revisional bariatric surgery after sleeve gastrectomy: a systematic review and meta analysis. Obes Surg 35(12):5515 to 5530 (PMCID: PMC12722500) 41193797 10.1007/s11695-025-08325-2 PMC12722500
10. Aderinto N, Olatunji G, Kokori E, Olaniyi P, Isarinade T, Yusuf IA (2023) Recent advances in bariatric surgery: a narrative review of weight loss procedures. Ann Med Surg (Lond) 85(12):6091 to 6104 38098582 10.1097/MS9.0000000000001472 PMC10718334
11. Hany M, Zidan A, Elmongui E, Torensma B (2022) Revisional Roux-en-Y gastric bypass versus revisional one-anastomosis gastric bypass after failed sleeve gastrectomy: a randomized controlled trial. Obes Surg 32(11):3491 to 3503 36098907 10.1007/s11695-022-06266-8 PMC9469810
12. Haider MI, Kaur M, Jamal Z, Almerie Q, Darrien J, Stewart D, Javed MS, Kerrigan DD (2024) Outcomes of single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): a single bariatric center experience. Cureus 16(12):e76150. https://pubmed.ncbi.nlm.nih.gov/39834997/. Cited 2025 Dec 2026 10.7759/cureus.76150 PMC11745527 39834997
13. Pokala B, Giannopoulos S, Athanasiadis DI, Motamedi SMK, Stefanidis D (2023) Distal gastric bypass revision for weight recurrence or nonresponse to primary procedure: initial experience and outcomes in an academic practice. Surg Endosc 37(7):5538 to 5546 (PMID: 36261645) 36261645 10.1007/s00464-022-09719-4
14. Zaveri H, Surve A, Cottam D, Cottam A, Medlin W, Richards C, Belnap L, Cottam S, Horsley B (2018) Mid-term 4-year outcomes with single anastomosis duodenal-ileal bypass with sleeve gastrectomy surgery at a single US center. Obes Surg 28(10):3062 to 3072 (PMID: 29909514) 29909514 10.1007/s11695-018-3358-x
15. Enochs P, Bull J, Surve A, Cottam D, Bovard S, Bruce J, Tyner M, Pilati D, Cottam S (2020) Comparative analysis of the single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) to established bariatric procedures: an assessment of 2-year postoperative data illustrating weight loss, type 2 diabetes, and nutritional status in a single US center. Surg Obes Relat Dis 16(1):24 to 33 (PMID: 31753795) 31753795 10.1016/j.soard.2019.10.008
16. Alimi Y, Azagury DE (2021) Gastroesophageal reflux disease and the patient with obesity. Gastroenterol Clin North Am 50(4):859 to 870 (PMID: 34717875) 34717875 10.1016/j.gtc.2021.08.010
17. Brown WA, de Leon Ballesteros GP, Ooi G, Higa K, Himpens J, Torres A, Shikora S, Kow L, Herrera MF, IFSO appointed task force reviewing the literature on SADI-S/OADS (2021) Single anastomosis duodenal-ileal bypass with sleeve gastrectomy/one anastomosis duodenal switch (SADI-S/OADS) IFSO position statement-update 2020. Obes Surg 31(1):3 to 25 (PMID: 33409979) 33409979 10.1007/s11695-020-05134-7
18. Gerges WB, Omran H, Makram F (2022) Conversion of laparoscopic sleeve gastrectomy after weight loss failure into laparoscopic one anastomosis gastric bypass: short-term safety and efficacy and effect of indications on outcome. Surg Endosc 36(2):1080 to 1089 (PMID: 33625589) 33625589 10.1007/s00464-021-08374-5
19. Marincola G, Velluti V, Voloudakis N, Gallucci P, Ciccoritti L, Greco F, Sessa L, Salvi G, Iaconelli A, Aquilanti B, Guidone C, Capristo E, Mingrone G, Pennestrì F, Raffaelli M (2023) Medium-term nutritional and metabolic outcome of single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Nutrients 15(3):742 (PMCID: PMC9921544) 36771446 10.3390/nu15030742 PMC9921544
20. Baird E, Schreuder H, Thompson K (2025) Robotic single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S): adverse outcomes compared to gastric sleeve and Roux-en-Y gastric bypass from a high-volume bariatric center. Mini-invasive Surg 9:18
21. El-Masry H, Zidan MH, Hany M, Abokhozima A (2025) Nutritional concerns in the meta-analysis comparing SADI and OAGB as revisional procedures following sleeve gastrectomy. Obes Surg 35(3):1178 to 1181 (PMID: 39961920) 39961920 10.1007/s11695-025-07684-0
22. Pažusis M, Gerasimovič G, Petereit R, Gudaitytė R, Maleckas A (2024) GERD after Roux-en-Y gastric bypass: prevalence and risk factors analysis. Medicina (Kaunas) 60(8):1221 (PMCID: PMC11356576) 39202502 10.3390/medicina60081221 PMC11356576
23. Bhatt A, Ahuja RN, Nguyen AD (2025) GERD management in the patient with obesity: diagnostic and therapeutic considerations. Current Treatment Options in Gastroenterology. https://www.springermedicine.com/gastroesophageal-reflux-disease/obesity/gerd-management-in-the-patient-with-obesity-diagnostic-and-thera/51055988. Cited 2025 Dec 26
Publication and source details

Original title: Comparative seven year outcomes of RYGB and SADI-S as revisional procedures for weight recurrence regain after sleeve gastrectomy: weight loss trajectory, reflux control, and metabolic safety

Asaad F. Salama; Abdelwahed Yahmadi; Hamzah El Baba; Jawher Baazaoui; Khadija Gibreal; Mohamed Bougmiza; Mohammed Al Kuwari

Surgical Endoscopy · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Hamad Medical Corporation

Open Access funding provided by the Qatar National Library.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:43:10.583858+00:00

DOI: 10.1007/s00464-026-12692-x · PMC13161284